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Abstract
Background Weak muscle strength has been associated with a wide range of adverse health outcomes. Yet, whether
individuals with weaker muscle strength are more at risk for hospitalization due to severe COVID-19 is still unclear.
The objective of this study was to investigate the independent association between muscle strength and COVID-19
hospitalization.
Methods Data from adults 50 years of age or older were analysed using logistic models adjusted for several chronic
conditions, body-mass index, age, and sex. Hand-grip strength was repeatedly measured between 2004 and 2017 using
a handheld dynamometer. COVID-19 hospitalization during the lockdown was self-reported in summer 2020 and was
used as an indicator of COVID-19 severity.
Results The study was based on the Survey of Health, Ageing and Retirement in Europe (SHARE) and included
3600 older adults (68.8 ± 8.8 years, 2044 female), among whom 316 were tested positive for the severe acute
respiratory syndrome coronavirus 2 (8.8%), and 83 (2.3%) were hospitalized due to COVID-19. Results showed that
higher grip strength was associated with a lower risk of COVID-19 hospitalization [adjusted odds ratio (OR) per
increase of 1 standard deviation in grip strength = 0.64, 95% confidence interval (95% CI) = 0.45–0.87,
P = 0.015]. Results also showed that age (OR for a 10 -year period = 1.70, 95% CI = 1.32–2.20, P < 0.001)
and obesity (OR = 2.01, 95% CI = 1.00–3.69, P = 0.025) were associated with higher risk of COVID-19 hospitali-
zation. Sensitivity analyses using different measurements of grip strength as well as robustness analyses based on
rare-events logistic regression and a different sample of participants (i.e. COVID-19 patients) were consistent with
the main results.
Conclusions Muscle strength is an independent risk factor for COVID-19 severity in adults 50 years of age or older.
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Introduction
As of February 2021, more than 100 million people were
diagnosed with the coronavirus disease 2019 (COVID-19),
and over 2 million died due to this infection.1 The majority
of infected people are asymptomatic2,3 or have mild
symptoms such as fever, cough, dyspnoea, fatigue, or
anosmia/dysgeusia.4,5 However, severe COVID-19 symptoms
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can also be life-threatening and require hospitalization.6
Thus, identifying risk factors for severe COVID-19 is important
to inform clinical decisions and public-health strategies.
Several risk factors have already been identified, includ-
ing older age, male sex, and underlying health conditions
such as obesity, cardiovascular disease, respiratory disease,
kidney disease, diabetes, and cancer.7–9 In addition to these
established risk factors for severe COVID-19, the latest
studies suggest that physical fitness should also be
considered.10–12 For example, maximum exercise capacity
was associated with the risk of COVID-19 hospitalization,11
slower walkers showed higher risk of severe COVID-19 than
brisk walkers,12 and the overall level of fitness was associ-
ated with survival in COVID-19 hospitalized patients.13
Whether muscle strength, another dimension of physical fit-
ness, is a risk factor for severe COVID-19 remains unclear.
Muscle strength is an indicator of muscle function, which is
essential to health14,15 and has shown to be a robust predictor
of multiple diseases and all-cause mortality.14,16–18 Therefore,
muscle strength should be considered as a potential risk fac-
tor for severe COVID-19.19 The objective of this study was to
investigate the association between muscle strength and
COVID-19 severity. We hypothesized that maximum muscle
strength would be inversely associated with COVID-19
hospitalization, independently of established risk factors.
Methods
Study overview
Data from the Survey of Health, Ageing and Retirement in
Europe (SHARE) were collected every two years between
2004 and 2017 (7 waves of data collection) on adults
50 years of age or older living in 27 European countries
(n = 139,556). From June to September 2020, SHARE partic-
ipants (n = 52,310) responded to additional questions in
the SHARE COVID-19 questionnaire.20 Questions included
whether they had been tested positive for the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and
whether this infection had resulted in hospitalization. To
be included in the study, participants should be aged
50 years or older, have completed at least one regular
(not COVID-19) SHARE questionnaire between 2004 and
2017. They should also have indicated whether they were
infected by the SARS-CoV-2 and/or whether they were
hospitalized due to COVID-19 in the SHARE COVID-19 ques-
tionnaire (Figure 1). SHARE was approved by the Ethics
Committee of the University of Mannheim (Waves 1–4)
and the Ethics Council of the Max Plank Society (Waves
4–7).
Figure 1 Flow chart.
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Hospitalization due to COVID-19 was derived from the ques-
tion ‘Have you, or anyone close to you, been hospitalized
due to an infection from the coronavirus?’. If participants an-
swered ‘yes’, the interviewer asked who was hospitalized.
Participants who indicated they were hospitalized were
included in the analyses as COVID-19 hospitalized. If the
participant indicated that their ‘spouse or partner’ was hospi-
talized, the spouse or partner was included in the analyses as
COVID-19 hospitalized.
Independent variable: muscle strength
Hand-grip strength (kg) was used as an indicator of muscle
strength and was measured twice with each hand (alternat-
ing between hands) using a handheld dynamometer
(Smedley, S Dynamometer, TTM, Tokyo, 100 kg). Participants
were instructed to stand (preferably) or sit with the elbow
flexed at a 90° angle, the wrist in a neutral position, and
the upper arm in a vertical position against the trunk. Inter-
viewers delivered standardized instructions to ensure that
the grip was performed with maximum effort. The maximum
value collected in either hand was used as an indicator of
muscle strength in the main analyses.14,21 Grip strength was
assessed at each data-collection wave, but only the most
recent measurement of maximum grip strength was included
in the main analyses.
Covariates and established risk factors
The following covariates were included in the analysis: Age
(in 2020, when responding to the SHARE COVID-19
questionnaire), sex (male or female), height (cm), body-mass
index (normal: <25, overweight: ≥25 and <30, obese:
≥30 kg/m2), cardiovascular disease (heart attack, including
myocardial infarction or coronary thrombosis, or any other
cardiovascular problem including congestive heart failure,
high blood cholesterol, high blood pressure or hypertension,
and stroke or cerebral vascular disease), respiratory disease
(including chronic bronchitis or emphysema, and asthma),
diabetes, cancer, chronic kidney disease, and rheumatoid
arthritis. All these covariates are established risk factors for
severe COVID-197–9 and were measured using question-
naires. When a participant had multiple measures across
the different waves of data collection, the most recent
measurement was included in the analyses. As
recommended,17,22,23 self-reported height (cm) was included
in the analyses to ensure that the association observed
between muscle strength and COVID-19 hospitalization was
not due to a difference in height.
Data analyses
Main analyses
Three logistic regression models were fitted. Model 0 tested
the association between muscle strength and COVID-19
hospitalization, adjusting for height. Model 1 tested the asso-
ciation between the established risk factors (i.e. age, sex,
height, body-mass index, cardiovascular disease, respiratory
disease, diabetes, cancer, chronic kidney disease, and
rheumatoid arthritis) and COVID-19 hospitalization. Model 2
tested the association between grip strength and COVID-19
hospitalization, while adjusting for the established risk fac-
tors. Age was centred on mean age (i.e. 68.8 years) and di-
vided by 10, so that the coefficient reflected the effects of
increased odds of COVID-19 hospitalization over a 10-year
period.24 Grip strength was standardized so that the coeffi-
cient reflected the effects associated with an increase of 1
standard deviation (SD). The multiple logistic regression
models account for the variance shared between muscle
strength, age, and health-related conditions, thereby
assessing whether muscle strength was independently associ-
ated with COVID-19 hospitalization. In other words, the
models examined the association between muscle strength
and COVID-19 hospitalization over and above the influence
of the established risk factors for severe COVID-19 (i.e. age,
sex, height, body-mass index, cardiovascular disease, respira-
tory disease, diabetes, cancer, chronic kidney disease, and
rheumatoid arthritis). Statistical analyses were conducted in
R using the glm package. Statistical assumptions associated
with general logistic models were met (i.e. normality of the
residuals, multicollinearity, and undue influence). To illustrate
the association between grip strength and COVID-19 hospital-
ization from the estimates obtained in Model 2, we com-
puted the odds ratio of hospitalization in individuals with
weaker grip strength and stronger grip strength by centring
grip strength on mean  1SD and mean + 1SD, respectively.
Sensitivity analyses
Three sensitivity analyses were conducted. In the first sensi-
tivity analysis, average grip strength over the study duration
(i.e. from Wave 1 to 7) replaced the most recent measure-
ment to test the association with a more stable level of
muscle strength. The second sensitivity analysis included grip
strength assessed only in the wave preceding the SHARE
COVID-19 questionnaire (i.e. Wave 7) (N = 2,884) to shorten
the time between the measure of grip strength and the
COVID-19 hospitalization event. The third sensitivity analysis
adjusted for the country of residence (Belgium, Bulgaria,
Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Hungary, Israel, Italy, Latvia,
Lithuania, Luxembourg, Malta, the Netherlands, Poland,
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and
Switzerland).
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Robustness analyses
Two robustness analyses were conducted. In the first
robustness analysis, the dataset was analysed using a
rare-events logistic regression,25 which corrects for the bias
associated with rare events. To account for the estimated
fraction of patients hospitalized due to COVID-19 in the Eu-
ropean population from June to September 2020, we used
a tau parameter of 84/100,000 based on COVID-19
hospitalization data that were available from May 2020
(Supporting information, Table S1). These data likely
underrepresent the true number of COVID-19 hospitaliza-
tions, as hospitalizations that occurred earlier than May
2020 were not included, thereby making the analysis more
conservative. In addition, we corrected for our case–control
sampling design using the weighting method (R Zelig
package).26 The second robustness analysis included only
patients who tested positive for COVID-19 (N = 316) to ex-
amine whether muscle strength is a risk factor in the
population of COVID-19 patients. This subsample was gen-
erated based on the question ‘Have you, or anyone close
to you, been tested for the coronavirus and the result
was positive, meaning that you or the person had the
COVID disease?’
Results
The study sample included 3600 individuals (68.8 ± 8.8 years,
2044 female), of whom 316 were tested positive for the
SARS-CoV-2 (8.8%) and 83 (2.3%) were hospitalized due to
COVID-19 (Figure 1). Table 1 summarizes the characteristics
of the participants stratified by COVID-19 hospitalization
status. Descriptively, COVID-19 hospitalization (vs. no
hospitalization) was associated with older age (P < 0.001),
higher body-mass index (P = 0.064), cardiovascular disease
(P = 0.079), chronic kidney disease (P = 0.052), and weaker
muscle strength (P = 0.027). The number of participants
who completed their last measure of grip strength in Waves
1, 2, 3, 4, 5, 6, and 7 was 10, 7, 3, 39, 188, 413, and 2940,
respectively.
Univariate model
Model 0 showed that the most recent measure of maximum
grip strength was associated with COVID-19 hospitalization
[adjusted odds ratio (OR) = 0.60, 95% confidence interval
Table 1 Sample characteristics by hospitalization status
Not hospitalized (N = 3517) Hospitalized (N = 83) P value
Studied factor
Muscle strength (kg, SD) 34.5 11.8 31.9 11.4 0.027*
Established risk factors
Age (years, SD) 68.8 8.6 73.0 10.7 <0.001
Sex
Female 1986 56.5% 43 51.2%
Male 1531 43.5% 40 48.2% 0.463
Body-mass index (kg/m2)
Normal: <25 1411 40.1% 24 28.9%
Overweight: ≥25 and <30 1420 40.4% 36 43.4%
Obese: ≥30 686 19.5% 23 27.7% 0.064
Cardiovascular disease
No 1721 48.9% 32 38.6%
Yes 1796 51.1% 51 61.4% 0.079
Respiratory disease
No 3336 94.9% 75 90.4%
Yes 181 5.1% 8 9.6% 0.118
Diabetes
No 3177 90.3% 71 85.5%
Yes 340 9.7% 12 14.5% 0.206
Cancer
No 3365 95.7% 80 96.4%
Yes 152 4.3% 3 3.6% 0.968
Rheumatoid arthritis
No 3229 91.8% 73 88.0%
Yes 288 8.2% 10 12.0% 0.289
Chronic kidney disease
No 3464 98.5% 79 95.2%
Yes 53 1.5% 4 4.8% 0.052
Note. P values are based on the analyses of variance and χ2 tests for continuous and categorical variables, respectively, testing the asso-
ciation between hospitalization (vs. non-hospitalization) and these variables. SD = standard deviation;
*P value is based on muscle strength accounting for height.
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(95% CI) = 0.45–0.81, P < 0.001, per increase of 1 SD in grip
strength] (Table 2).
Established risk factors and COVID-19
hospitalization
Model 1 showed that older individuals were at higher risk of
COVID-19 hospitalization compared with younger individuals
(OR = 1.70, 95% CI = 1.32–2.20, P < 0.001). The odds ratio
was also higher in obese individuals than in individuals with
a normal body-mass index (OR = 2.01, 95% CI = 1.09–3.69,
P = 0.025). The other associations were not statistically signif-
icant (Ps > 0.089) (Table 2).
Grip strength and COVID-19 hospitalization
Model 2 showed that the most recent measure of maximum
grip strength (34.43 ± 11.79 kg; mean ± SD) was
associated with the risk of COVID-19 hospitalization
(OR = 0.64, 95% CI = 0.45–0.92, P = 0.015 per increase of 1
SD in grip strength) (Table 2). The odds ratio was more than
twice higher in individuals with weaker grip strength
(mean  1SD = 22.64 kg, OR = 0.019, 95% CI = 0.01–0.03,
P < 0.001), compared with individuals with stronger grip
strength (mean + 1SD = 46.22 kg, OR = 0.008, 95%
CI = 0.003–0.016, P < 0.001) (Figure 2). When grip strength
was included in the model, the association of age
(OR = 1.50, 95% CI = 1.14–1.97, P = 0.003) and body-mass
index (OR = 2.11, 95% CI = 1.14–3.88, P = 0.016) with
COVID-19 hospitalization remained significant (Table 2).
Table 2 Results of the logistic models testing the association of established risk factors and grip strength with COVID-19 hospitalization
Model 0 Model 1 Model 2
Variables OR (95% CI) P OR (95% CI) P OR (95% CI) P
Intercept 0.02 (0.02; 0.03) <0.001 0.015 (0.01; 0.02) <0.001 0.012 (0.01; 0.02) <0.001
Hand-grip strength 0.60 (0.45; 0.81) <0.001 0.64 (0.45; 0.92) 0.015
Height 1.54 (1.15; 2.04) 0.003 1.31 (0.96; 1.77) 0.089 1.06 (1.06; 2.00) 0.020
Age 1.70 (1.32; 2.20) <0.001 1.50 (1.14; 1.97) 0.003
Sex (ref. female)
Male 0.79 (0.43; 1.43) 0.427 1.26 (0.62; 2.51) 0.518
Body-mass index (ref. normal)
Overweight 1.44 (0.85; 2.49) 0.179 1.53 (0.90; 2.64) 0.121
Obese 2.01 (1.09; 3.69) 0.025 2.11 (1.14; 3.88) 0.016
Cardiovascular disease (ref. no)
Yes 1.06 (0.66; 1.73) 0.811 1.03 (0.64; 1.67) 0.912
Respiratory disease (ref. no)
Yes 1.52 (0.66; 3.08) 0.278 1.50 (0.65; 3.05) 0.295
Diabetes (ref. No)
Yes 1.19 (0.59; 2.19) 0.601 1.09 (0.54; 2.01) 0.806
Cancer (ref. No)
Yes 0.67 (0.16; 1.85) 0.504 0.63 (0.15; 1.74) 0.438
Rheumatoid arthritis (ref. no)
Yes 1.17 (0.55; 2.24) 0.669 1.07 (0.50; 2.07) 0.850
Chronic kidney disease (ref. no)
Yes 2.44 (0.71; 6.41) 0.104 2.29 (0.66; 6.05) 0.134
95% CI, 95% confidence interval; OR, odds ratio.
Note. Age was centred on mean age (i.e. 68.8 years) and divided by 10 so that the coefficient reflected the effects of an increased odds of
COVID-19 hospitalization over a 10 year period. Hand-grip strength was standardized so that the coefficient reflected the effects associ-
ated with an increase of 1 standard deviation (i.e. 11.79 kg).
Figure 2 Association between hand-grip strength and the odds of being hospitalized due to COVID-19. Note. Odds ratios (OR) were adjusted for age,
sex, height, body-mass index, cardiovascular disease, respiratory disease, chronic kidney disease, rheumatoid arthritis, diabetes, and cancer (Model 2).
95% CI, 95% confidence interval.
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Sensitivity and robustness
The sensitivity (Tables S2–S4) and robustness analyses (Tables
S5 and S6) yielded similar results to those of the main analy-
ses. Specifically, results of the sensitivity analyses showed that
muscle strength averaged across the 7 waves (OR = 0.62, 95%
CI = 0.42–0.92, p = 0.017), muscle strength assessed only in
wave 7 (OR = 0.65, 95% CI = 0.44–0.96, p = 0.029), and the
most recent measure of maximum grip strength in the model
adjusting for the country of residence (OR = 0.67, 95%
CI = 0.46–0.98, p = 0.036) were associated with the risk of
COVID-19 hospitalization. Results of the robustness analysis
based on the rare-events logistic regression showed that the
most recent measure of maximum grip strength was associ-
ated with the risk of COVID-19 hospitalization (OR = 0.63,
95% CI = 0.43–0.92, p = 0.016). Finally, results of the robust-
ness analysis that included only patients who tested positive
for COVID-19 showed that the most recent measure of maxi-
mum grip strength was associated with the risk of COVID-19
hospitalization (OR = 0.56, 95% CI = 0.33–0.94, p = 0.031).
Discussion
Recent findings suggest that physical fitness should be con-
sidered as a risk factor for severe COVID-19.10–12 Here, mus-
cle strength was assessed using hand-grip strength, and
severe COVID-19 was derived from self-reported COVID-19
hospitalization. Results showed that weaker muscle strength
was associated with a higher risk of severe COVID-19, which
lends direct empirical support to this hypothesized relation-
ship. Moreover, this association was observed after adjusting
for established risk factors for severe COVID-19. The latter
result suggests that muscle strength was associated with
COVID-19 hospitalization, independent of older age, male
sex, and health-related conditions including obesity,
cardiovascular disease, respiratory disease, diabetes, cancer,
chronic kidney disease, and rheumatoid arthritis.
The association between muscle strength and COVID-19 se-
verity can be explained by the essential role of muscle in
health and disease.15 In particular, skeletal muscle weakness
has been shown to affect the motor and respiratory function
and has been linked to poor immune response and metabolic
stress when facing acute infection.19,27–29 Therefore, adults
with weaker muscle strength may be more vulnerable to
SARS-CoV-2 infection and at higher risk of developing severe
forms of COVID-19. This hypothesis is indirectly supported
by previous results. For example, some conditions associated
with muscle weakness such as older age, chronic disease, and
cancer have been identified as risk factors for COVID-19
severity.30–32 Likewise, patients with sarcopenia have been as-
sociated with an impaired respiratory function,33 which is the
function affected by SARS-CoV-2. Finally, our findings are
consistent with recent studies showing that other dimensions
of physical fitness are associated with an increased risk of
COVID-19 hospitalization.10–13 Of note, in older patients, the
SARS-CoV-2 infection has been shown to increase the risk of
muscle loss and acute sarcopenia.19,34,35 Therefore, a vicious
cycle between muscle weakness and COVID-19 could occur,
with muscle weakness increasing COVID-19 severity, which
in turn could trigger muscle-mass loss and muscle-strength
decline,19 thereby negatively affecting the patients’ condition.
Among the strengths of the present study are the large
sample size, the longitudinal design, and a measure of
hand-grip strength based on a well-established procedure.
Moreover, the results were consistent across multiple inde-
pendent variables, different statistical approaches, and two
different population samples (i.e. general population and pa-
tients tested positive for COVID-19). However, potential limi-
tations should be noted. First, the established risk factors
were assessed with questionnaires, which may have reduced
measurement validity. Second, the latest assessment of these
factors was in 2017, 2 years before participants’ potential
COVID-19 infection. Therefore, participants may have
contracted a disease sometime between the assessment of
these health conditions and the COVID-19 pandemic, which
may have resulted in a misclassification bias. Third,
COVID-19 severity was inferred by COVID-19 hospitalization.
However, this measure lacks sensitivity. For example, the
questionnaire did not assess the duration of hospitalization
or whether the patients were transferred to an
intensive-care unit, which would have allowed a more
nuanced assessment of COVID-19 severity. Similarly, our
sample did not include participants who were hospitalized
during data collection (except when the information could
be extracted from the spouse or partner) and participants
who died due to COVID-19. These limitations may explain
the absence of statistical evidence supporting the effect of
established risk factors for COVID-19 hospitalization.36,37
Conclusions
This study shows that muscle strength is independently
associated with the risk of severe COVID-19 in adults 50 years
of age or older. These findings further highlight muscle
strength as an important factor to monitor in COVID-19
patients,19,34,38 thereby suggesting that hand-grip strength
could improve the accuracy of composite scores used to
predict COVID-19 severity.19,39,40
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